RESTORALAX 100 %
POLYETHYLENE GLYCOL 3350 : 100 % · DIN 02318164 · BAYER INC
Health Canada status: MARKETED
What is RESTORALAX?
RESTORALAX 100 % contains POLYETHYLENE GLYCOL 3350 : 100 %. It is listed in the Health Canada Drug Product Database under DIN 02318164, held by BAYER INC, supplied as POWDER FOR SOLUTION for ORAL administration. Health Canada currently lists it as marketed, status dated 12-Jan-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02318164 |
|---|---|
| Brand name | RESTORALAX |
| Generic / active ingredient | POLYETHYLENE GLYCOL 3350 : 100 % |
| Manufacturer | BAYER INC |
| Strength | 100 % |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | ORAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | A06AD15 MACROGOL |
| AHFS class | 56:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 12-Jan-2017 |
| Original market date | 2009-10-16 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code A06AD15 MACROGOL. 12 of 22 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CLEARLAX | 100 % | POWDER FOR SOLUTION | PERRIGO INTERNATIONAL | MARKETED | DIN 02324989 |
| COLAXOR | 100 % | POWDER FOR SOLUTION | MANTRA PHARMA INC | MARKETED | DIN 02450070 |
| COMFILAX | 100 % | POWDER FOR SOLUTION | CELLCHEM PHARMACEUTICALS INC. | MARKETED | DIN 02460297 |
| EMOLAX | 100 % | POWDER FOR SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02374137 |
| HYDRALAX | 17 G | POWDER FOR SOLUTION | JUNO OTC INC | MARKETED | DIN 02473119 |
| LAX-A-DAY | 100 % | POWDER FOR SOLUTION | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 02317680 |
| LAX-A-DAY PHARMA | 100 % | POWDER FOR SOLUTION | PHARMASCIENCE INC | MARKETED | DIN 02453193 |
| LAXATIVE | 100 % | POWDER FOR SOLUTION | PHARMASCIENCE INC | MARKETED | DIN 02548933 |
| PEG 3350 | Strength | Powder For Solution | MEDISCA PHARMACEUTIQUE INC 6090 Henri Bourassa West St-Laurent Quebec Canada H4R 3A6 | MARKETED | DIN 02358034 |
| PEG 3350 | Strength | Powder For Solution | ANGITA PHARMA INC. 1310 Rue Nobel Boucherville Quebec Canada J4B 5H3 | MARKETED | DIN 02520796 |
Who else supplies MACROGOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MACROGOL appears in 61 registered pack listings across 9 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.